New research indicates that marijuana could alleviate some of the worst effects experienced by cancer patients undergoing chemotherapy. Tilray (NASDAQ:TLRY) announced Monday that a clinical trial in... Tilray Reports Positive Results For Medical Marijuana In Chemotherapy Patients

New research indicates that marijuana could alleviate some of the worst effects experienced by cancer patients undergoing chemotherapy. Tilray (NASDAQ:TLRY) announced Monday that a clinical trial in Australia has demonstrated positive results in reducing the nausea and vomiting common to people enduring such treatments for their illness.

The phase 2 study comprised 81 patients, who were dosed three times per day with capsules of either marijuana supplied by Tilray or a placebo, according to an entry in the Annals of Oncology. This was accompanied by dosing with antiemetics, i.e. medications that suppress nausea and vomiting. The researchers found “significant improvement” in the control of those reactions.

Tilray specified that a quarter of the study’s participants taking the marijuana experienced no vomiting or nausea at all, against 14% of those who were administered the placebo.

There were, however, side effects such as dizziness and drowsiness, which were reported in around one-third of the patients. These participants demonstrated moderate to severe forms of these effects, but Tilray said the study’s researchers consider these to be manageable. [Read more at International Business Times]

MJ Shareholders avatar

MJ Shareholders

MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers

No comments so far.

Be first to leave comment below.

( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )